Key facts
- It has raised $20.0M; the latest was Grant ($3.7M) in Apr 2025.
- Notable investors include Insight Partners (New York), Boehringer Ingelheim Venture Fund, CARB-X, Viva BioInnovator, Arimed Advisors — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for ArrePath
- ·The full record, as it builds
Funding rounds
No funding rounds for ArrePath are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ArrePath
Operator of a drug discovery platform intended to develop antimicrobial resistance therapies. The company's platform helps create new medicines that modulate several targets in the disease pathway, potentially improving efficacy and minimizing risk in the discovery and development process, enabling healthcare professionals to treat chronic ailments and reduce recovery time.
- Sector
- Healthcare
- HQ
- Princeton, NJ, United States
- Founded
- 2021
- Employees
- 16
- Website
- arrepath.com/
- Ownership
- Privately Held (backing)
ArrePath doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ArrePath shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ArrePath in its N-PORT filings yet. We sweep new filings monthly.